WO2005033099A3 - Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof - Google Patents

Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof Download PDF

Info

Publication number
WO2005033099A3
WO2005033099A3 PCT/IB2004/003206 IB2004003206W WO2005033099A3 WO 2005033099 A3 WO2005033099 A3 WO 2005033099A3 IB 2004003206 W IB2004003206 W IB 2004003206W WO 2005033099 A3 WO2005033099 A3 WO 2005033099A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
dipeptidyl peptidase
compositions
processes
preparation
Prior art date
Application number
PCT/IB2004/003206
Other languages
French (fr)
Other versions
WO2005033099A2 (en
Inventor
Balasubramanian Gopalan
Hemant Vasant Joshi
Daisy Manish Shah
Sandeep Raghunath Ghorpade
Original Assignee
Glenmark Pharmaceuticals Ltd
Balasubramanian Gopalan
Hemant Vasant Joshi
Daisy Manish Shah
Sandeep Raghunath Ghorpade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd, Balasubramanian Gopalan, Hemant Vasant Joshi, Daisy Manish Shah, Sandeep Raghunath Ghorpade filed Critical Glenmark Pharmaceuticals Ltd
Publication of WO2005033099A2 publication Critical patent/WO2005033099A2/en
Publication of WO2005033099A3 publication Critical patent/WO2005033099A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula (I), and their analogs, isomers, pharmaceutical compositions and therapeutic uses, methods of making the same.
PCT/IB2004/003206 2003-10-03 2004-10-01 Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof WO2005033099A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1039/MUM/2003 2003-10-03
IN1039MU2003 2003-10-03
US51736003P 2003-11-04 2003-11-04
US60/517,360 2003-11-04

Publications (2)

Publication Number Publication Date
WO2005033099A2 WO2005033099A2 (en) 2005-04-14
WO2005033099A3 true WO2005033099A3 (en) 2005-06-30

Family

ID=34424919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003206 WO2005033099A2 (en) 2003-10-03 2004-10-01 Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof

Country Status (1)

Country Link
WO (1) WO2005033099A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004033902A1 (en) 2004-07-14 2006-02-16 Zentaris Gmbh New tetrahydrocarbazole compounds are neurokinin-1 receptor antagonists useful to treat or prevent e.g. pubertas praecox, hirsutism, polycystic ovary syndrome, hormone dependent neoplastic diseases and Alzheimer's disease
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
ZA200708179B (en) * 2005-04-22 2009-12-30 Alantos Pharmaceuticals Holding Inc Dipeptidyl peptidase-IV inhibitors
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
MX2009001105A (en) 2006-08-07 2009-02-10 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives.
WO2009037719A1 (en) 2007-09-21 2009-03-26 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US8748457B2 (en) 2009-06-18 2014-06-10 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
EP2558447B1 (en) 2010-03-22 2014-09-17 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
HUE028972T2 (en) 2011-04-14 2017-01-30 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013139929A1 (en) * 2012-03-22 2013-09-26 Ludwig-Maximilians-Universität München Novel means and methods for treating diseases of the central nervous system, metabolic and cardiac diseases and aging
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2015233029B2 (en) 2014-03-17 2018-11-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
KR20160133536A (en) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN104402798B (en) * 2014-10-21 2016-09-14 杭州瑞德化工有限公司 A kind of 3-amino-1, the method for splitting of 2,3,4-tetrahydro carbazoles
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EA201791982A1 (en) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY
BR112017027656B1 (en) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019998A2 (en) * 1996-11-07 1998-05-14 Novartis Ag N-substituted 2-cyanopyrrolidines
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
US6124305A (en) * 1996-11-07 2000-09-26 Novartis Ag Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV
WO2003002530A2 (en) * 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019998A2 (en) * 1996-11-07 1998-05-14 Novartis Ag N-substituted 2-cyanopyrrolidines
US6124305A (en) * 1996-11-07 2000-09-26 Novartis Ag Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
WO2003002530A2 (en) * 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
WO2005033099A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2005033099A3 (en) Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
TW200614988A (en) Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
IL173802A0 (en) Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2003002531A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002530A3 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
TW200612892A (en) Novel compounds
EP1819674A4 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MXPA05012026A (en) Azaindole compounds as kinase inhibitors.
WO2006020276A3 (en) Antiviral compounds
MXPA05010682A (en) Novel compounds.
WO2007009109A3 (en) Antiviral compounds
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2002014311A3 (en) Urea compounds and methods of uses
WO2006039325A3 (en) Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MXPA03010207A (en) Novel 4-anilinoquinoline-3-carboxamides.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA91688C2 (en) Antiviral compounds
WO2004096234A3 (en) Kinase inhibitor phosphonate conjugates
TW200519075A (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase